Kurze, Anna-Katharina
Buhs, Sophia
Eggert, Dennis
Oliveira-Ferrer, Leticia
Müller, Volkmar
Niendorf, Axel
Wagener, Christoph
Nollau, Peter
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (031B0066B)
Article History
Received: 25 March 2019
Accepted: 14 August 2019
First Online: 27 August 2019
Ethics approval and consent to participate
: For studies on normal breast tissues as well as corresponding serum samples, all patients gave written informed consent to access their tissue/serum and to review their medical records, in accordance with our investigational review board and the ethics committee of the Medical Board Hamburg which approved this study (reference No. 190504). Studies on human breast cancer samples were approved by the local ethical review board and all patients gave written informed consent to access their tissue and to review their medical records (Ärztekammer Hamburg, Germany, PV3548). For studies on tissue microarrays written informed consent was given by all donors and samples were collected under Health Insurance Portability and Accountability Act (HIPPA)–approved protocols as stated by US Biomax.
: Not applicable.
: AN, PN and CW hold a patent on the detection of glycans using the carbohydrate recognition domain of CLEC10A (CD301). AKK, SB, DE, LOF and VM declare no competing interests.